Monoclonal Antibodies Market by Product Type, Distribution Channel, End User 2023-2028

Author: Elena Anderson, Marketing Manager |

Group

Report DescriptionAbout IMARC Group

The International Market Analysis Research and Consulting Group is a leading adviser on management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, chemicals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

IMARC’s tailored approach combines unfathomable insight into the dynamics of companies and markets with close cooperation at all levels of the client organization. This ensures that our clients achieve unmatchable competitive advantage, build more proficient organizations, and secure lasting results.

Global Monoclonal Antibodies Market Research Report:

The latest report by IMARC, titled “ MonoclonalAntibodiesMarket:GlobalIndustryTrends,Share,Size,Growth,OpportunityandForeca st2023-2028

” " the global monoclonal antibodies market reached a value of US$ 207.4 Billion in 2022.

Monoclonal antibodies (mAb) are produced by a single clone of cells or cell lines and consist of identical antibody molecules. These antibodies can have monovalent affinity, binding only to the same epitope. Due to their site-specificity, these serve as essential tools to detect or purify substances. They are being used on a clinical level to diagnose and treat several diseases.

They are used as probes to identify materials in laboratories or home-testing kits. Due to their specificity to unique epitopes, monoclonal antibodies are widely used for diagnostic and therapeutic applications for several diseases. Several manufacturers are focusing on creating medications from many classifications to treat various disorders, including cancer and rare diseases. Monoclonal antibodies, in combination with chemotherapeutic drugs, are extensively being used to treat different malignancies.

Request Free Sample Report: https://www.imarcgroup.com/monoclonal-antibodies-market/requestsample

Global Monoclonal Antibodies Market Trends:

The global market is majorly driven by the increasing prevalence of chronic diseases, such as cancer and cardiovascular diseases. In line with this, the rising demand for biologics and the growing applications of monoclonal antibodies for targeted therapies are significantly contributing to the market. This is attributed to the escalating awareness about such treatments among patients and physicians. Furthermore, various key players are undertaking strategic initiatives to develop and market mAb products. Apart from this, the heavy investments by top pharmaceutical companies in genomics research and development activities are positively influencing the market.

Moreover, the increasing requirement for effective and affordable therapies for cancer treatment is catalyzing the market. Besides, an extensive product pipeline with potential effective therapies catering to a diverse range of diseases is propelling the market expansion. Additionally, the augmenting focus on the discovery and development of novel monoclonal antibody therapeutics to offer treatment for complex and severe diseases is bolstering the monoclonal antibodies market. On account of the factors above, the market is anticipated to reach a value of US$ 307.8 Billion by 2028, exhibiting a CAGR of 6.9% during 2023-2028.

Looking forward, the market value is projected to reach a strong growth during the forecast period (2023-2028).

Report Description Report Description and Highlights

MarketSummary:

BreakupbyProductionMethod:

• In Vivo

• In Vitro

BreakupbySource:

• Murine

• Chimeric

• Humanized

• Human

BreakupbyIndication:

• Cancer

• Autoimmune Diseases

• Inflammatory Diseases

• Infectious Diseases

• Others

Report Description Report Description and Highlights

BreakupbyEndUse:

• Hospitals

• Research Institutes

• Others

BreakupbyRegion:

• North America

• United States

• Canada

• Asia-Pacific

• China

• Japan

• India

• South Korea

• Australia

• Indonesia

• Others

• Europe

• Germany

• France

• United Kingdom

• Italy

• Spain

• Russia

• Others

• Latin America

• Brazil

• Mexico

• Others

• Middle East and Africa

CompetitiveLandscapewithKeyPlayers:

• AbbVie Inc

• Amgen Inc.

• Biogen Inc.

• F. Hoffmann-La Roche AG

• GSK plc

• Johnson & Johnson

• Merck KGaA

• Novartis AG

• Novo Nordisk A/S

• Pfizer Inc.

• Sanofi S.A.

• Thermo Fisher Scientific Inc.

ViewFullReportwithTOC&ListofFigure:

https://www.imarcgroup.com/monoclonal-antibodies-market

A partial List of our Clients

Partial List of Clients

We are the trusted business partners to the world's leading corporates, governments, and institutions

A partial List of our Clients

Partial List of Clients

We are the trusted business partners to the world's leading corporates, governments, and institutions

Report Description Report Description and Highlights

© 2019 IMARC All Rights Reserved

This Publication and all it’s contents unless otherwise mentioned are copyrighted in the name of International Market Analysis Research and Consulting (IMARC). No part of this publication may be reproduced, repackaged, redistributed or resold in whole or in any part. The publication may also not be used in any form or by and means graphic electronic or mechanical, including photocopying, recording, taping or by information storage or retrieval, or by any other form, without the express consent of International Market Analysis Research and Consulting (IMARC).

Disclaimer: All contents and data of this publication, including forecasts, data analysis and opinion have been based on information and sources believed to be accurate and reliable at the time of publishing. International Market Analysis Research and Consulting makes no representation of warranty of any kind as to the accuracy or completeness of any Information provided. IMARC accepts no liability whatsoever for any loss or damage resulting from opinion, errors or inaccuracies if any found this publication.

IMARC, IMARC Group and Global Therapy Insight Series are registered trademarks of International Market Analysis Research and Consulting. All other trademarks used in this publication are registered trademarks of their respective companies.